MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, TGTX has $1,528,837K in assets. $945,706K in debts. $442,209K in cash and cash equivalents.

Balance Sheets Overview

Current Ratio
580.93%
Quick Ratio
511.97%
Cash Ratio
236.34%
Debt to Asset Ratio
61.86%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Accounts receivable, net
    • Deferred tax assets
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Loan payable non-current
    • Others

Balance Sheets
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Cash and cash equivalents
442,209 79,148 74,081 129,126
Short-term investment securities
72,221 62,822 57,501 122,744
Accounts receivable, net
392,046 305,628 265,384 231,516
Inventory
129,029 125,586 146,953 155,202
Other current assets
51,464 57,580 55,846 25,374
Total current assets
1,086,969 630,764 599,765 663,962
Restricted cash
1,352 1,342 1,329 1,316
Long-term investment securities
61,538 59,136 48,757 28,590
Right of use assets
6,481 6,278 6,501 6,718
Deferred tax assets
344,136 348,000 366,627 -
Non-current inventories
26,346 15,689 --
Other noncurrent assets
2,015 2,044 2,045 2,027
Total assets
1,528,837 1,063,253 1,025,024 702,613
Accounts payable and accrued expenses
148,845 107,508 112,336 134,021
Other current liabilities
596 2,124 1,993 2,256
Lease liability current portion
1,822 1,044 1,068 1,091
Deferred revenue - current portion
17,190 21,234 26,399 23,911
Accrued compensation
18,655 21,850 15,014 10,610
Total current liabilities
187,108 153,760 156,810 171,889
Deferred revenue, non-current portion
6,863 8,807 8,348 1,667
Loan payable non-current
745,140 245,645 245,340 245,037
Lease liability non-current
6,595 7,021 7,308 7,588
Total liabilities
945,706 415,233 417,806 426,181
Common stock, 0.001 par value per share (190,000,000 and 190,000,000 shares authorized, 159,965,425 and 158,849,596 shares issued, 153,093,879 and 155,305,953 shares outstanding at march 31, 2026 and december 31, 2025, respectively)
160 159 159 159
Additional paid-in capital
1,845,435 1,830,110 1,812,345 1,794,212
Treasury stock, at cost, 3,543,643 and 367,903 shares at december 31, 2025 and december 31, 2024
-100,234 100,234 -
Treasury stock, at cost, 6,871,546 and 3,543,643 shares at march 31, 2026 and december 31, 2025, respectively
200,226 --21,992
Accumulated deficit
-1,062,238 -1,082,015 -1,105,052 -1,495,947
Total stockholders equity
583,131 648,020 607,218 276,432
Total liabilities and stockholders equity
1,528,837 1,063,253 1,025,024 702,613
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$442,209K Accounts receivable, net$392,046K Inventory$129,029K Short-term investmentsecurities$72,221K Other current assets$51,464K Total current assets$1,086,969K Deferred tax assets$344,136K Long-term investmentsecurities$61,538K Non-current inventories$26,346K Right of use assets$6,481K Other noncurrentassets$2,015K Restricted cash$1,352K Total assets$1,528,837K Total liabilities andstockholders equity$1,528,837K Total liabilities$945,706K Total stockholdersequity$583,131K Accumulated deficit-$1,062,238K Treasury stock, at cost,6,871,546 and 3,543,643...$200,226K Loan payable non-current$745,140K Total currentliabilities$187,108K Deferred revenue,non-current portion$6,863K Lease liability non-current$6,595K Additional paid-in capital$1,845,435K Common stock, 0.001 parvalue per share...$160K Accounts payable andaccrued expenses$148,845K Accrued compensation$18,655K Deferred revenue -current portion$17,190K Lease liability current portion$1,822K Other currentliabilities$596K

TG Therapeutics BRIUMVI Approval Call Slide Deck 12

TG THERAPEUTICS, INC. (TGTX)

TG Therapeutics BRIUMVI Approval Call Slide Deck 12

TG THERAPEUTICS, INC. (TGTX)